Assessment of quality of life as outcome in dementia and MCI intervention trials: A systematic review

Alzheimer Disease and Associated Disorders

Volumn 21, Issue 2, 2007, Pages 172-178

  Schölzel Dorenbos, Carla J M ^a   Van Der Steen, Mariëlle J M M ^a   Engels, Lotte K ^a   Olde Rikkert, Marcel G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Caregiver; Dementia; Intervention studies; MCI; Quality of life; Responsiveness; Systematic review

Indexed keywords

CYANOCOBALAMIN; DONEPEZIL; ESSENTIAL OIL; FOLIC ACID; NAPROXEN; OLANZAPINE; PLACEBO; PYRIDOXINE; RISPERIDONE; ROFECOXIB; TESTOSTERONE;

AROMATHERAPY; BEHAVIOR THERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITIVE DEFECT; COGNITIVE THERAPY; COMMUNITY CARE; DEMENTIA; DISEASE EXACERBATION; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RATING SCALE; RELIABILITY; REVIEW; TREATMENT OUTCOME; VALIDITY; WALKING;

COGNITION DISORDERS; DEMENTIA; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 34249937262     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318047df4c     Document Type: Review

References (52)

1. De Korte J, Mombers FM, Sprangers MA, et al. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol. 2002;138:1221-1227.
2. Rockwood K, Gauthier S, eds. Trial Designs and Outcomes in Dementia Therapeutic Research. London and New York: Taylor & Francis Group; 2006.
3. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653-666.
4. Rockwood K, Stolee P. Responsiveness of outcome measures used in an antidementia drug trial. Alzheimer Dis Assoc Disord. 2000;14:182-185.
5. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord. 1996;10(suppl 1):31-35.
6. Banerjee S, Smith SC, Lamping DL, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry. 2006;77:146-148.
7. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395-407.
8. Walker MD, Salek SS, Bayer AJ. A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact. Pharmacoeconomics. 1998;14:499-530.
9. Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimer's disease. Neurology. 2005;64:S34-S39.
10. Lyketsos CG, Gonzales-Salvador T, Chin JJ, et al. A follow-up study of change in quality of life among persons with dementia residing in a long-term care facility. Int J Geriatr Psychiatry. 2003;18:275-281.
11. Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol. 2004;18:351-363.
12. Barrett B, Brown D, Mundt M, et al. Sufficiently important difference: expanding the framework of clinical significance. Med Decision Making. 2005;25:250-261.
13. Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes. 2006;4:69.
14. Schunemann HJ, Akl EA, Guyatt GH. Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective. Health Qual Life Outcomes. 2006;4:62.
15. Brod M, Stewart AL, Sands L, et al. Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL). Gerontologist. 1999;39:25-35.
16. Logsdon RG, Gibbons LE, McCurry SM, et al. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64:510-519.
17. Scocco P, Fantoni G, Caon F. Role of depressive and cognitive status in self-reported evaluation of quality of life in older people: comparing proxy and physician perspectives. Age Ageing. 2006;35:166-171.
18. Bowling A. Measuring Health: A Review of Quality of Life Measurement Scales. Milton Keynes, Philadelphia: Open University Press; 1993.
19. Spilker B. Quality of Life Assessment in Clinical Trials. New York: Raven Press; 1990.
20. de Haes JC, van Knippenberg FC. The quality of life of cancer patients: a review of the literature. Soc Sci Med. 1985;20:809-817.
21. Joyce CRB, O'Boyle CA, McGee H. Individual Quality of Life. Approaches to Conceptualisation and Assessment. Singapore: Harwood Academic publishers; 1999.
22. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials. 1991;12:142S-158S.
23. Beaton DE, Bombardier C, Katz JN, et al. A taxonomy for responsiveness. J Clin Epidemiol. 2001;54:1204-1217.
24. de Vet HC, Terwee CB, Ostelo RW, et al. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes. 2006;4:54.
25. Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63:177-185.
26. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021-1031.
27. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
28. Ballard CG, O'Brien JT, Reichelt K, et al. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002;63:553-558.
29. Lai CK, Chi I, Kayser-Jones J. A randomized controlled trial of a specific reminiscence approach to promote the well-being of nursing home residents with dementia. Int Psychogeriatr. 2004;16:33-49.
30. Logiudice D, Waltrowicz W, Brown K, et al. Do memory clinics improve the quality of life of carers? A randomized pilot trial. Int J Geriatr Psychiatry. 1999;14:626-632.
31. Teri L, McCurry SM, Logsdon R, et al. Training community consultants to help family members improve dementia care: a randomized controlled trial. Gerontologist. 2005;45:802-811.
32. Politis AM, Vozzella S, Mayer LS, et al. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry. 2004;19:1087-1094.
33. Spector A, Thorgrimsen L, Woods B, et al. Efficacy of an evidencebased cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry. 2003;183:248-254.
34. van Uffelen JG, Hopman-Rock M, Chin APM, et al. Protocol for Project FACT: a randomised controlled trial on the effect of a walking program and vitamin B supplementation on the rate of cognitive decline and psychosocial wellbeing in older adults with mild cognitive impairment [ISRCTN19227688]. BMC Geriatr. 2005;5:18.
35. Blau TH. Quality of life, social indicators and criteria of change. Prof Psychol. 1977;8:464-473.
36. Martin-Cook K, Hynan LS, Rice-Koch K, et al. Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia. Dement Geriatr Cogn Disord. 2005;19:82-85.
37. Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ. 2006;174:1099-1105.
38. Woods B, Thorgrimsen L, Spector A, et al. Improved quality of life and cognitive stimulation therapy in dementia. Aging Ment Health. 2006;10:219-226.
39. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;CD005593.
40. Rockwood K, Stolee P, Howard K, et al. Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology. 1996;15:330-338.
41. Kaduszkiewicz H. An innovative approach to involve patients in measuring treatment effects in drug trials. CMAJ. 2006;174:1117-1118.
42. Patterson M, Whitehouse P, Barber M, et al. Psychological assessment of QOL in drug trials. Int Psychogeriatr. 2005;17:31-32.
43. Selwood A, Thorgrimsen L, Orrell M. Quality of life in dementia - a one-year follow-up study. Int J Geriatr Psychiatry. 2005;20:232-237.
44. Fossey J, Lee L, Ballard C. Dementia Care Mapping as a research tool for measuring quality of life in care settings: psychometric properties. Int J Geriatr Psychiatry. 2002;17:1064-1070.
45. Schölzel-Dorenbos CJM, Ettema TP, Bos J, et al. Evaluating the outcome of interventions on quality of life in dementia: selection of the appropriate scale. Int J Geriatr Psychiatry. 2006. [Epub ahead of print.].
46. Coen R, O'Mahony D, O'Boyle C, et al. Measuring the quality of life of dementia patients using the Schedule for the Evaluation of Individual Quality of Life. Irish J Psychol. 1993;14:154-163.
47. McGee HM, O'Boyle CA, Hickey A, et al. Assessing the quality of life of the individual: the SEIQoL with a healthy and a gastroenterology unit population. Psychol Med. 1991;21:749-759.
48. Schölzel-Dorenbos CJM. Measurement of quality of life in patients with dementia of Alzheimer type and their caregivers: Schedule for the Evaluation of Individual Quality of Life (SEIQoL). Tijdschr Gerontol Geriatr. 2000;31:23-26.
49. Hoe J, Katona C, Roch B, et al. Use of the QOL-AD for measuring quality of life in people with severe dementia-the LASER-AD study. Age Ageing. 2005;34:130-135.
50. Ettema TP, Droes RM, de Lange J, et al. QUALIDEM: development and evaluation of a dementia specific quality of life instrument. Scalability, reliability and internal structure. Int J Geriatr Psychiatry. 2006. [Epub ahead of print.].
51. Hoogendoorn LI, Kamp S, Mahomed CA, et al. The role of observer for the reliability of Dutch version of the Discomfort Scale-Dementia of Alzheimer Type (DS-DAT). Tijdschr Gerontol Geriatr. 2001;32:117-121.
52. Revicki DA, Cella D, Hays RD, et al. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70.